Omalizumab as a treatment option for antihistamine-refractory aquagenic urticaria. Issue 7 (18th July 2022)

• Record Type: Journal Article
• Authors: Kaur, Sehajpreet; Jabbal, Iktej Singh; Bhasin, Arveen Kaur
• Is Part Of: BMJ case reports. Volume 15:Issue 7(2022)
• Publication Date: 2022-07-18
• Subjects: Dermatology -- Immunology; Medicine -- Case studies -- Periodicals; 610.5
• DOI: 10.1136/bcr-2022-251057
• Languages: English
• ISSNs: 1757-790X

Abstract

Abstract : A teenage girl presented with symptoms of itching and hives on contact with water for 3 years. On specific provocative testing and ruling out underlying systemic conditions, she was diagnosed with aquagenic urticaria. Following failed attempts to control her symptoms with second-generation antihistamines, she was started on monthly subcutaneous injections of the monoclonal antibody, omalizumab. The patient demonstrated significant improvement, with symptoms being well-controlled for 2 years now. She enjoys a good quality of life and can take a shower without developing itching or hives.